Paclitaxel-loaded polymeric depots as injectable drug delivery system for cancer chemotherapy of hepatocellular carcinoma

Pharm Dev Technol. 2017 Aug;22(5):652-658. doi: 10.3109/10837450.2016.1163389. Epub 2016 Apr 7.

Abstract

In this work, paclitaxel-encapsulated polymeric depots were prepared and characterized as drug delivery system for cancer chemotherapy against hepatocellular carcinoma. Effects of different parameters, including drug-loading content, polymer concentration and depot weight on depot formation, percentage of sustained-release taxol and drug release profile were evaluated. Paclitaxel-loaded depots were successfully formed at the polymer concentration above 25% w/v. For all formulations, paclitaxel could be encapsulated with very high percentage of sustained-release taxol (>90%). The release rate of paclitaxel from depots could be controlled by the amount of drug-loading content, polymer concentration and depot weight. Cytotoxicity against liver cancer cell line, HepG2, was evaluated by medium extraction method. Paclitaxel releasing from depots showed cytotoxic effect against HepG2 at different incubation times, whereas blank depots exhibited no cytotoxicity.

Keywords: Biodegradable polymers; drug delivery system; paclitaxel; polymeric depot.

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Carcinoma, Hepatocellular / drug therapy*
  • Cell Line, Tumor
  • Drug Carriers*
  • Drug Delivery Systems
  • Humans
  • Liver Neoplasms / drug therapy*
  • Paclitaxel*

Substances

  • Antineoplastic Agents
  • Drug Carriers
  • Paclitaxel